NCT06644352 Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma
| NCT ID | NCT06644352 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Condition | Siewert Type II Adenocarcinoma of Esophagogastric Junction |
| Study Type | INTERVENTIONAL |
| Enrollment | 236 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 236 participants in total. It began in 2022-07-01 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To explore the 5-year overall survival (OS) of right versus left thoracic surgical approaches for patients with locally advanced Siewert II gastroesophageal junction adenocarcinoma treated by neoadjuvant chemotherapy
Eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed gastroesophageal adenocarcinoma; 2. R0 resectable Siewert Ⅱ, cT2-3N0-3M0 (AJCC V8 TNM classification); 3. Have a performance status of 0 or 1 on the ECOG Performance Scale; 4. Age 18-80 years old, both men and women; 5. Estimated survival ≥6 months; 6. Be willing and able to provide written informed consent/assent for the trial; 7. Demonstrate adequate organ function ; 8. Female subject of childbearing potential should have a negative urine or serum pregnancy within 7 days before enrollment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; 9. Have not received systemic or local treatment for esophageal cancer in the past. Exclusion Criteria: 1. Have a history of other malignant tumors in the past or at the same time; 2. Previous upper abdominal surgery (excluding cholecystectomy); 3. Bleeding, perforation and obstruction requiring emergency surgical treatment; 4. Severe heart, lung, liver and kidney dysfunction, which the researcher thinks is not suitable for operation; 5. Hydrothorax and ascites with clinical symptoms need therapeutic puncture or drainage; 6. Participate in other clinical studies or less than 1 month from the end of the previous clinical study; 7. Have a history of psychoactive drug abuse, alcoholism or drug abuse; 8. Be unable or do not agree to bear the inspection and treatment expenses at their own expense; 9. The researcher thinks that it should be excluded from this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06644352 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Siewert Type II Adenocarcinoma of Esophagogastric Junction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06644352 currently recruiting?
Yes, NCT06644352 is actively recruiting participants. Contact the research team at liyin@cicams.ac.cn for enrollment information.
Where is the NCT06644352 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06644352 clinical trial?
NCT06644352 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The trial plans to enroll 236 participants.